- Home
- GLPG vs KWR Comparison
GLPG vs KWR Comparison
Compare GLPG & KWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- KWR
- Stock Information
- Founded
- GLPG 1999
- KWR 1918
- Country
- GLPG Belgium
- KWR United States
- Employees
- GLPG N/A
- KWR N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- KWR Major Chemicals
- Sector
- GLPG Health Care
- KWR Industrials
- Exchange
- GLPG Nasdaq
- KWR Nasdaq
- Market Cap
- GLPG 2.0B
- KWR 2.2B
- IPO Year
- GLPG 2005
- KWR 1985
- Fundamental
- Price
- GLPG $32.98
- KWR $114.31
- Analyst Decision
- GLPG Sell
- KWR Strong Buy
- Analyst Count
- GLPG 4
- KWR 5
- Target Price
- GLPG $25.33
- KWR $155.40
- AVG Volume (30 Days)
- GLPG 372.1K
- KWR 187.1K
- Earning Date
- GLPG 07-23-2025
- KWR 07-31-2025
- Dividend Yield
- GLPG N/A
- KWR 1.69%
- EPS Growth
- GLPG N/A
- KWR N/A
- EPS
- GLPG N/A
- KWR 5.29
- Revenue
- GLPG $323,674,692.00
- KWR $1,812,841,000.00
- Revenue This Year
- GLPG $0.78
- KWR $1.16
- Revenue Next Year
- GLPG N/A
- KWR $5.16
- P/E Ratio
- GLPG N/A
- KWR $21.67
- Revenue Growth
- GLPG 5.43
- KWR N/A
- 52 Week Low
- GLPG $22.36
- KWR $95.91
- 52 Week High
- GLPG $33.86
- KWR $184.79
- Technical
- Relative Strength Index (RSI)
- GLPG 64.82
- KWR 42.72
- Support Level
- GLPG $31.98
- KWR $117.38
- Resistance Level
- GLPG $33.51
- KWR $125.72
- Average True Range (ATR)
- GLPG 0.84
- KWR 4.36
- MACD
- GLPG 0.13
- KWR -1.28
- Stochastic Oscillator
- GLPG 82.68
- KWR 9.26
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.